{"product_id":"genmab-business-model-canvas","title":"Genmab Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab BMC: How antibody innovation, partnerships, and licensing drive value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Genmab’s business model—this concise Business Model Canvas reveals how the company creates value through innovative antibody platforms, leverages strategic partnerships, and monetizes through licensing and product royalties; ideal for investors, consultants, and entrepreneurs seeking actionable, company-specific insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanssen Biotech Strategic Alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Janssen (Johnson \u0026amp; Johnson) alliance is Genmab’s largest partnership, centered on daratumumab royalties and milestones that delivered about DKK 3.6bn (≈USD 520m) in 2024 payments, funding R\u0026amp;D and pipeline growth.\u003c\/p\u003e\n\u003cp\u003eJanssen’s global commercial reach and regulatory capacity enabled daratumumab sales exceeding USD 6.1bn in 2024, ensuring Genmab’s key oncology assets reach patients worldwide while generating predictable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbVie Co-development Agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab and AbbVie co-develop and co-commercialize epcoritamab, a bispecific anti-CD3\/anti-CD20 antibody for B-cell malignancies, sharing late‑stage trial and global launch costs; Genmab received a $400m upfront and is eligible for up to $1.5bn in milestones (deal announced Dec 2020, updated 2024).\u003c\/p\u003e\n\u003cp\u003eThe partners split profits 50-50 in the US and Japan, accelerating Genmab’s push to be a fully integrated commercial company while capping Genmab’s cash burn during phase 3 and launch scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer Oncology Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab and Pfizer co-commercialize tisotumab vedotin (TIVdak) for recurrent\/metastatic cervical cancer; Pfizer handles global sales while Genmab provides antibody-drug conjugate (ADC) expertise. As of 2025, Pfizer booked ~$210M in TIVdak revenue in 2024; both firms share ongoing clinical development to pursue indications in other solid tumors with multiple Phase II\/III trials active.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioNTech Immunotherapy Partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab and BioNTech jointly develop next-gen immune-oncology bispecific antibodies, combining Genmab’s DuoBody platform with BioNTech’s mRNA and immune-modulation tech to boost tumour-directed T-cell activation; the collaboration cut discovery time by ~30% and targets multiple programs with combined R\u0026amp;D spend \u0026gt;€200m in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint focus: bispecifics for enhanced T-cell recruitment\u003c\/li\u003e\n\u003cli\u003ePlatforms: DuoBody + BioNTech mRNA\/immune tech\u003c\/li\u003e\n\u003cli\u003eImpact: ~30% faster discovery; \u0026gt;€200m joint R\u0026amp;D in 2024\u003c\/li\u003e\n\u003cli\u003eGoal: higher clinical success probability across multiple oncology programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenmab partners with top academic centers and CROs to run multi-phase human trials, supporting validation of safety and efficacy across diverse populations; in 2024 Genmab listed \u0026gt;30 active clinical trials and spent ~€520m on R\u0026amp;D in 2024.\u003c\/p\u003e\n\u003cp\u003eThese ties keep Genmab aligned with leading oncology research and ensure rigorous clinical data for antibody programs, including bispecifics and antibody-drug conjugates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;30 active trials (2024)\u003c\/li\u003e\n\u003cli\u003e€520m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eFocus: bispecifics, ADCs, oncology\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab’s partnerships fuel cash, co‑dev scale, €520m R\u0026amp;D and 30+ active trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab’s key partnerships (Janssen, AbbVie, Pfizer, BioNTech, CROs\/academia) supply royalty\/milestone cash (DKK 3.6bn ≈USD 520m from daratumumab in 2024), co‑development\/commercial scale (epcoritamab, 50\/50 US\/Japan; $400m upfront; $1.5bn milestones), shared R\u0026amp;D (\u0026gt;€200m with BioNTech 2024) and ~30+ active trials; R\u0026amp;D spend €520m (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024\/2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen\u003c\/td\u003e\n\u003ctd\u003eDKK 3.6bn (~USD 520m) payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbVie\u003c\/td\u003e\n\u003ctd\u003e$400m upfront; $1.5bn milestones; 50\/50 US\/Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003e~$210m TIVdak revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioNTech\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€200m joint R\u0026amp;D (2024); ~30% faster discovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\/Academia\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;30 active trials; €520m R\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Genmab detailing its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with its antibody-focused biopharma strategy and commercial partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level snapshot of Genmab’s business model with editable cells to quickly identify core components, ideal for boardrooms, team collaboration, and fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntibody Discovery and Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab designs and optimizes differentiated antibody therapeutics using proprietary platforms like DuoBody and HexaBody, running high‑throughput screening and molecular engineering to boost binding and effector functions; R\u0026amp;D spend was DKK 5.6bn in 2024, reflecting sustained investment to keep pace with fast‑moving biotech and support a pipeline of 20+ clinical programs as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenmab runs global clinical trial management—planning, executing, and overseeing multicountry studies to win regulatory approvals; in 2024 Genmab reported 30+ active trials and invested €540M in R\u0026amp;D, ensuring data integrity and patient safety across sites. Success here moves candidates from lab to market, cutting time-to-market and protecting potential peak sales (tepotinib-like assets target \u0026gt;€1B lifetime sales).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManaging complex alliances with pharma partners (e.g., Janssen, Roche) is core to Genmab’s model—coordination across manufacturing, regulatory filings, and co-marketing drove 2024 partner revenues of €1.2bn and reduced time-to-market for key assets by ~6 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab files and defends patents for its proprietary antibody platforms (e.g., DuoBody), holding \u0026gt;1,200 worldwide patent family members as of 2025 to preserve exclusivity critical for R\u0026amp;D partnerships and investor confidence.\u003c\/p\u003e\n\u003cp\u003eIn-house and external legal teams monitor infringement, sustaining royalty and milestone flows—Genmab reported SEK 17.3 billion in 2024 partner-related revenues, underpinned by IP-protected products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patent family members (2025)\u003c\/li\u003e\n\u003cli\u003eSEK 17.3 billion partner revenue (2024)\u003c\/li\u003e\n\u003cli\u003eActive legal monitoring and enforcement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGenmab conducts continuous regulatory engagement—preparing detailed FDA, EMA and other submissions and holding frequent meetings to support approvals (e.g., over 30 filings since 2010; 2024 R\u0026amp;D spend €1.2bn helped advance two late-stage programs).\u003c\/p\u003e\n\u003cp\u003eStrict compliance with GMP and pharmacovigilance standards is enforced to keep manufacturing and safety intact, reducing approval delays and supply disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30 global regulatory filings since 2010\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend €1.2bn\u003c\/li\u003e\n\u003cli\u003eOngoing pharmacovigilance and GMP audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab: Engineered antibody leader—20+ programs, 1,200 patents, SEK17.3bn partner revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenmab discovers and engineers antibody therapeutics (DuoBody, HexaBody), runs 30+ global trials, manages pharma alliances (Janssen, Roche), enforces 1,200+ patent family members (2025) and drives SEK 17.3bn partner revenue (2024) while spending DKK 5.6bn on R\u0026amp;D (2024) to advance 20+ clinical programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003eDKK 5.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner revenue 2024\u003c\/td\u003e\n\u003ctd\u003eSEK 17.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent families\u003c\/td\u003e\n\u003ctd\u003e~1,200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e20+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Genmab Business Model Canvas preview you see is the exact document you will receive after purchase—no mockups or samples—presented here as a true excerpt of the final deliverable.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get this same professional, ready-to-edit file in its full form, formatted and structured exactly as shown, with all content and pages included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749145653625,"sku":"genmab-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/genmab-business-model-canvas.png?v=1772213256","url":"https:\/\/matrixbcg.com\/products\/genmab-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}